메뉴 건너뛰기




Volumn 92, Issue 6, 2012, Pages 746-756

Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: Systematic review and meta-analysis

(40)  Danese, E a   Montagnana, M a   Johnson, J A b   Rettie, A E c   Zambon, C F d   Lubitz, S A e   Suarez Kurtz, G f   Cavallari, L H g   Zhao, L h   Huang, M h   Nakamura, Y i   Mushiroda, T j   Kringen, M K k   Borgiani, P l   Ciccacci, C l   Au, N T c   Langaee, T b   Siguret, V m   Loriot, M A m   Sagreiya, H n,o   more..


Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; COUMARIN ANTICOAGULANT; CYTOCHROME P450 2C9; CYTOCHROME P450 4F2; CYTOCHROME P450 ISOENZYME; MENADIONE EPOXIDE; PHENPROCOUMON; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN;

EID: 84869497712     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.184     Document Type: Article
Times cited : (63)

References (50)
  • 1
    • 4644230820 scopus 로고    scopus 로고
    • The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    • DOI 10.1378/chest.126.3-suppl.204S
    • Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A. & Hylek, E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126, 204S-233S (2004). (Pubitemid 39297955)
    • (2004) Chest , vol.126 , Issue.SUPPL. 3
    • Ansell, J.1    Hirsh, J.2    Poller, L.3    Bussey, H.4    Jacobson, A.5    Hijlek, E.6
  • 2
    • 81855169543 scopus 로고    scopus 로고
    • Emergency hospitalizations for adverse drug events in older Americans
    • Budnitz, D.S., Lovegrove, M.C., Shehab, N. & Richards, C.L. Emergency hospitalizations for adverse drug events in older Americans. N. Engl. J. Med. 365, 2002-2012 (2011).
    • (2011) N. Engl. J. Med , vol.365 , pp. 2002-2012
    • Budnitz, D.S.1    Lovegrove, M.C.2    Shehab, N.3    Richards, C.L.4
  • 4
    • 83055174032 scopus 로고    scopus 로고
    • Role of pharmacogenomics in the management of traditional and novel oral anticoagulants
    • Cavallari, L.H., Shin, J. & Perera, M.A. Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy 31, 1192-1207 (2011).
    • (2011) Pharmacotherapy , vol.31 , pp. 1192-1207
    • Cavallari, L.H.1    Shin, J.2    Perera, M.A.3
  • 5
    • 66849132349 scopus 로고    scopus 로고
    • CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant
    • McDonald, M.G., Rieder, M.J., Nakano, M., Hsia, C.K. & Rettie, A.E. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol. 75, 1337-1346 (2009).
    • (2009) Mol. Pharmacol , vol.75 , pp. 1337-1346
    • McDonald, M.G.1    Rieder, M.J.2    Nakano, M.3    Hsia, C.K.4    Rettie, A.E.5
  • 6
    • 42149188553 scopus 로고    scopus 로고
    • CYP4F2 genetic variant alters required warfarin dose
    • Caldwell, M.D. et al. CYP4F2 genetic variant alters required warfarin dose. Blood 111, 4106-4112 (2008).
    • (2008) Blood , vol.111 , pp. 4106-4112
    • Caldwell, M.D.1
  • 7
    • 49849102081 scopus 로고    scopus 로고
    • The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure
    • Fava, C. et al. The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension 52, 373-380 (2008).
    • (2008) Hypertension , vol.52 , pp. 373-380
    • Fava, C.1
  • 8
    • 84864488076 scopus 로고    scopus 로고
    • Hypertension cardiovascular risk and polymorphisms in genes controlling the cytochrome P450 pathway of arachidonic acid: A sex-specific relation?
    • Fava, C., Ricci, M., Melander, O. & Minuz, P. Hypertension, cardiovascular risk and polymorphisms in genes controlling the cytochrome P450 pathway of arachidonic acid: A sex-specific relation? Prostaglandins Other Lipid Mediat. 98, 75-85 (2012).
    • (2012) Prostaglandins Other Lipid Mediat , vol.98 , pp. 75-85
    • Fava, C.1    Ricci, M.2    Melander, O.3    Minuz, P.4
  • 9
    • 79961106952 scopus 로고    scopus 로고
    • Association of apolipoprotein e genotype with duration of time to achieve a stable warfarin dose in African-American patients
    • Cavallari, L.H. et al. Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients. Pharmacotherapy 31, 785-792 (2011).
    • (2011) Pharmacotherapy , vol.31 , pp. 785-792
    • Cavallari, L.H.1
  • 10
    • 79958108633 scopus 로고    scopus 로고
    • Effects of CYP4F2 and GGCX genetic variants on maintenance warfarin dose in a multi-ethnic Asian population
    • Chan, S.L. et al. Effects of CYP4F2 and GGCX genetic variants on maintenance warfarin dose in a multi-ethnic Asian population. Thromb. Haemost. 105, 1100-1102 (2011).
    • (2011) Thromb. Haemost , vol.105 , pp. 1100-1102
    • Chan, S.L.1
  • 11
    • 51649110496 scopus 로고    scopus 로고
    • A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
    • Cooper, G.M. et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112, 1022-1027 (2008).
    • (2008) Blood , vol.112 , pp. 1022-1027
    • Cooper, G.M.1
  • 12
    • 77951589703 scopus 로고    scopus 로고
    • Clinical assessment incorporating a personal genome
    • Ashley, E.A. et al. Clinical assessment incorporating a personal genome. Lancet 375, 1525-1535 (2010).
    • (2010) Lancet , vol.375 , pp. 1525-1535
    • Ashley, E.A.1
  • 13
    • 79955910555 scopus 로고    scopus 로고
    • Characterization of a novel CYP2C9 gene mutation and structural bioinformatic protein analysis in a warfarin hypersensitive patient
    • Ciccacci, C. et al. Characterization of a novel CYP2C9 gene mutation and structural bioinformatic protein analysis in a warfarin hypersensitive patient. Pharmacogenet. Genomics 21, 344-346 (2011).
    • (2011) Pharmacogenet. Genomics , vol.21 , pp. 344-346
    • Ciccacci, C.1
  • 14
    • 78650057287 scopus 로고    scopus 로고
    • Genetic and bioenvironmental factors associated with warfarin response in Colombian patients
    • Isaza, C. et al. [Genetic and bioenvironmental factors associated with warfarin response in Colombian patients]. Biomedica. 30, 410-420 (2010).
    • (2010) Biomedica , vol.30 , pp. 410-420
    • Isaza, C.1
  • 15
    • 65549085682 scopus 로고    scopus 로고
    • CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population
    • Borgiani, P. et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 10, 261-266 (2009).
    • (2009) Pharmacogenomics , vol.10 , pp. 261-266
    • Borgiani, P.1
  • 16
    • 79961134642 scopus 로고    scopus 로고
    • Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry
    • Botton, M.R., Bandinelli, E., Rohde, L.E., Amon, L.C. & Hutz, M.H. Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. Br. J. Clin. Pharmacol. 72, 442-450 (2011).
    • (2011) Br. J. Clin. Pharmacol , vol.72 , pp. 442-450
    • Botton, M.R.1    Bandinelli, E.2    Rohde, L.E.3    Amon, L.C.4    Hutz, M.H.5
  • 17
    • 77957959128 scopus 로고    scopus 로고
    • An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction
    • Carlquist, J.F. et al. An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction. J. Thromb. Thrombolysis 30, 358-364 (2010).
    • (2010) J. Thromb. Thrombolysis , vol.30 , pp. 358-364
    • Carlquist, J.F.1
  • 18
    • 77949873283 scopus 로고    scopus 로고
    • Genetic and clinical predictors of warfarin dose requirements in African Americans
    • Cavallari, L.H. et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin. Pharmacol. Ther. 87, 459-464 (2010).
    • (2010) Clin. Pharmacol. Ther , vol.87 , pp. 459-464
    • Cavallari, L.H.1
  • 19
    • 77954508907 scopus 로고    scopus 로고
    • CYP4F2 rs2108622: A minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement
    • Cen, H.J. et al. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br. J. Clin. Pharmacol. 70, 234-240 (2010).
    • (2010) Br. J. Clin. Pharmacol , vol.70 , pp. 234-240
    • Cen, H.J.1
  • 20
    • 78149256303 scopus 로고    scopus 로고
    • Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese
    • Cha, P.C. et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum. Mol. Genet. 19, 4735-4744 (2010).
    • (2010) Hum. Mol. Genet , vol.19 , pp. 4735-4744
    • Cha, P.C.1
  • 21
    • 84864349523 scopus 로고    scopus 로고
    • Translational aspects of genetic factors in the prediction of drug response variability: A case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia
    • Chan, S.L., Suo, C., Lee, S.C., Goh, B.C., Chia, K.S. & Teo, Y.Y. Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia. Pharmacogenomics J. 12, 312-318 (2012).
    • (2012) Pharmacogenomics J , vol.12 , pp. 312-318
    • Chan, S.L.1    Suo, C.2    Lee, S.C.3    Goh, B.C.4    Chia, K.S.5    Teo, Y.Y.6
  • 22
    • 79955486891 scopus 로고    scopus 로고
    • Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients
    • Choi, J.R. et al. Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. J. Hum. Genet. 56, 290-295 (2011).
    • (2011) J. Hum. Genet , vol.56 , pp. 290-295
    • Choi, J.R.1
  • 23
    • 81155137319 scopus 로고    scopus 로고
    • Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation
    • Gong, I.Y. et al. Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. PLoS ONE 6, e27808 (2011).
    • (2011) PLoS ONE , vol.6
    • Gong, I.Y.1
  • 24
    • 77956267130 scopus 로고    scopus 로고
    • Application of Akaike information criterion to evaluate warfarin dosing algorithm
    • Harada, T. et al. Application of Akaike information criterion to evaluate warfarin dosing algorithm. Thromb. Res. 126, 183-190 (2010).
    • (2010) Thromb. Res , vol.126 , pp. 183-190
    • Harada, T.1
  • 25
    • 79251588402 scopus 로고    scopus 로고
    • Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction
    • Kringen, M.K. et al. Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. J. Biomed. Biotechnol. 2011, 739751 (2011).
    • (2011) J. Biomed. Biotechnol , pp. 739751
    • Kringen, M.K.1
  • 26
    • 73649117856 scopus 로고    scopus 로고
    • Genetic determinants of warfarin dosing in the Han-Chinese population
    • Lee, M.T. et al. Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 10, 1905-1913 (2009).
    • (2009) Pharmacogenomics , vol.10 , pp. 1905-1913
    • Lee, M.T.1
  • 27
    • 77953745542 scopus 로고    scopus 로고
    • Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population
    • Lubitz, S.A. et al. Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J. Thromb. Haemost. 8, 1018-1026 (2010).
    • (2010) J. Thromb. Haemost , vol.8 , pp. 1018-1026
    • Lubitz, S.A.1
  • 28
    • 72849127064 scopus 로고    scopus 로고
    • Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients
    • Pautas, E. et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin. Pharmacol. Ther. 87, 57-64 (2010).
    • (2010) Clin. Pharmacol. Ther , vol.87 , pp. 57-64
    • Pautas, E.1
  • 30
    • 77955685235 scopus 로고    scopus 로고
    • Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9
    • Sagreiya, H. et al. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet. Genomics 20, 407-413 (2010).
    • (2010) Pharmacogenet. Genomics , vol.20 , pp. 407-413
    • Sagreiya, H.1
  • 31
    • 79951682471 scopus 로고    scopus 로고
    • Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients
    • Shahin, M.H. et al. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet. Genomics 21, 130-135 (2011).
    • (2011) Pharmacogenet. Genomics , vol.21 , pp. 130-135
    • Shahin, M.H.1
  • 32
  • 33
    • 79957902700 scopus 로고    scopus 로고
    • Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians
    • Suriapranata, I.M. et al. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. BMC Med. Genet. 12, 80 (2011).
    • (2011) BMC Med. Genet , vol.12 , pp. 80
    • Suriapranata, I.M.1
  • 34
    • 63449117825 scopus 로고    scopus 로고
    • A genome-wide association study confirms VKORC1 CYP2C9 and CYP4F2 As principal genetic determinants of warfarin Dose
    • Takeuchi, F. et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5, e1000433 (2009).
    • (2009) PLoS Genet , vol.5
    • Takeuchi, F.1
  • 35
    • 77952550801 scopus 로고    scopus 로고
    • A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism
    • Wells, P.S. et al. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: derivation in a sample with predominantly a history of venous thromboembolism. Thromb. Res. 125, e259-e264 (2010).
    • (2010) Thromb. Res , vol.125
    • Wells, P.S.1
  • 36
    • 78650466131 scopus 로고    scopus 로고
    • VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: An Italian retrospective study
    • Zambon, C.F. et al. VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. Pharmacogenomics 12, 15-25 (2011).
    • (2011) Pharmacogenomics , vol.12 , pp. 15-25
    • Zambon, C.F.1
  • 37
    • 70349574149 scopus 로고    scopus 로고
    • Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy
    • Zhang, J.E. et al. Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet. Genomics 19, 781-789 (2009).
    • (2009) Pharmacogenet. Genomics , vol.19 , pp. 781-789
    • Zhang, J.E.1
  • 38
    • 79960616137 scopus 로고    scopus 로고
    • Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose
    • Zhang, X., Li, L., Ding, X. & Kaminsky, L.S. Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. Drug Metab. Dispos. 39, 1433-1439 (2011).
    • (2011) Drug Metab. Dispos , vol.39 , pp. 1433-1439
    • Zhang, X.1    Li, L.2    Ding, X.3    Kaminsky, L.S.4
  • 39
    • 66549110050 scopus 로고    scopus 로고
    • Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy
    • Pérez-Andreu, V. et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 113, 4977-4979 (2009).
    • (2009) Blood , vol.113 , pp. 4977-4979
    • Pérez-Andreu, V.1
  • 40
    • 70350754462 scopus 로고    scopus 로고
    • A genome-wide association study of acenocoumarol maintenance dosage
    • Teichert, M. et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum. Mol. Genet. 18, 3758-3768 (2009).
    • (2009) Hum. Mol. Genet , vol.18 , pp. 3758-3768
    • Teichert, M.1
  • 41
    • 79953777152 scopus 로고    scopus 로고
    • Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters
    • Geisen, C. et al. Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters. Eur. J. Clin. Pharmacol. 67, 371-381 (2011).
    • (2011) Eur. J. Clin. Pharmacol , vol.67 , pp. 371-381
    • Geisen, C.1
  • 42
    • 78650680251 scopus 로고    scopus 로고
    • Dependency of phenprocoumon dosage on polymorphisms in the vKORC1 CYP2C9 and CYP4F2 genes
    • Teichert, M. et al. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes. Pharmacogenet. Genomics 21, 26-34 (2011).
    • (2011) Pharmacogenet. Genomics , vol.21 , pp. 26-34
    • Teichert, M.1
  • 43
    • 84861150804 scopus 로고    scopus 로고
    • Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and metaanalysis
    • Liang, R., Wang, C., Zhao, H., Huang, J., Hu, D. & Sun, Y. Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and metaanalysis. Thromb. Res. 130, 38-44 (2012).
    • (2012) Thromb. Res , vol.130 , pp. 38-44
    • Liang, R.1    Wang, C.2    Zhao, H.3    Huang, J.4    Hu, D.5    Sun, Y.6
  • 44
    • 62549143945 scopus 로고    scopus 로고
    • Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis
    • Lindh, J.D., Holm, L., Andersson, M.L. & Rane, A. Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis. Eur. J. Clin. Pharmacol. 65, 365-375 (2009).
    • (2009) Eur. J. Clin. Pharmacol , vol.65 , pp. 365-375
    • Lindh, J.D.1    Holm, L.2    Andersson, M.L.3    Rane, A.4
  • 45
    • 80052962391 scopus 로고    scopus 로고
    • Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing
    • Johnson, J.A. et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90, 625-629 (2011).
    • (2011) Clin. Pharmacol. Ther , vol.90 , pp. 625-629
    • Johnson, J.A.1
  • 46
    • 78349294600 scopus 로고    scopus 로고
    • Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial
    • French, B. et al. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 11, 108 (2010).
    • (2010) Trials , vol.11 , pp. 108
    • French, B.1
  • 47
    • 70649084116 scopus 로고    scopus 로고
    • Genotype-guided dosing of coumarin derivatives: The European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design
    • van Schie, R.M. et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 10, 1687-1695 (2009).
    • (2009) Pharmacogenomics , vol.10 , pp. 1687-1695
    • Van Schie, R.M.1
  • 48
    • 84862777241 scopus 로고    scopus 로고
    • A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II)
    • Anderson, J.L. et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 125, 1997-2005 (2012).
    • (2012) Circulation 125 , pp. 1997-2005
    • Anderson, J.L.1
  • 49
    • 77949567067 scopus 로고    scopus 로고
    • Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement-a systematic review and meta analysis
    • Yang, L., Ge, W., Yu, F. & Zhu, H. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement-a systematic review and meta analysis. Thromb. Res. 125, e159-e166 (2010).
    • (2010) Thromb. Res , vol.125
    • Yang, L.1    Ge, W.2    Yu, F.3    Zhu, H.4
  • 50
    • 34447266926 scopus 로고    scopus 로고
    • Functional polymorphism in human CYP4F2 decreases 20-HETE production
    • DOI 10.1152/physiolgenomics.00003.2007
    • Stec, D.E., Roman, R.J., Flasch, A. & Rieder, M.J. Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol. Genomics 30, 74-81 (2007). (Pubitemid 47173292)
    • (2007) Physiological Genomics , vol.30 , Issue.1 , pp. 74-81
    • Stec, D.E.1    Roman, R.J.2    Flasch, A.3    Rieder, M.J.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.